Molecular targets in the inhibition of angiogenesis

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 4, 2003, Pages 527-541

  Dudek, Arkadiusz Z ^a   Pawlak, Wojciethc Z ^b   Kirstein Pharm, Mark N ^a  

^a Center for Immunology   (United States)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Antiangiogenic therapy; Tumour angiogenesis; Vascular endothelial growth factor (VEGF)

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; CELECOXIB; CILENGITIDE; COLLAGEN; CYTOTOXIC AGENT; IM 862; INTEGRIN; INTERLEUKIN 12; MARIMASTAT; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY LM 609; PLASMINOGEN; REBIMASTAT; SQUALAMINE; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BASAL CELL CARCINOMA; BONE MARROW SUPPRESSION; BONE PAIN; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE MARKER; DRUG ACTIVITY; DRUG APPROVAL; DRUG TARGETING; DRUG WITHDRAWAL; ENDOTHELIUM; ERYTHEMA NODOSUM LEPROSUM; FOOD AND DRUG ADMINISTRATION; GENETIC STABILITY; HUMAN; HYPERTENSION; IMMUNOMODULATION; INHIBITION KINETICS; KAPOSI SARCOMA; KIDNEY CANCER; LIVER DISEASE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTIPLE MYELOMA; MYALGIA; NEUROPATHY; NEUTROPHIL CHEMOTAXIS; OVARY CANCER; PHAGOCYTOSIS; PHOTOSENSITIVITY; POLYMORPHONUCLEAR CELL; PROSTATE CANCER; REVIEW; SOLID TUMOR; SOMNOLENCE; TERATOGENICITY; THEORY; THROMBOEMBOLISM; TISSUE GROWTH; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANGIOPOIETINS; ANIMALS; CELL DIVISION; CLINICAL TRIALS; DRUG DESIGN; ENDOSTATINS; ENDOTHELIUM, VASCULAR; HUMANS; INTEGRINS; MATRIX METALLOPROTEINASES; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLATELET FACTOR 4; PROTEASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTORS, TIE; RECOMBINANT FUSION PROTEINS; THALIDOMIDE; THROMBOSPONDINS;

EID: 0042329420     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.4.527     Document Type: Review

References (190)

1. CHOI K: Hemangioblast development and regulation. Biochem. Cell Biol. (1998) 76:947-956.
2. COFFIN JD, POOLE TJ: Embryonic vascular development: immunohistochemical identification of the origin and subsequent morphogenesis of the major vessel primordia in quail embryos. Development (1988) 102:735-748.
3. PARDANAUD L, YASSINE F, DIETERLEN-LIEVRE F: Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. Development (1989) 105:473-485.
4. RISAU W: Mechanisms of angiogenesis. Nature (1997) 386:671-674.
5. TANNOCK IF: Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res. (1970) 30:2470-2476.
6. TANNOCK IF, STEEL GG: Tumor growth and cell kinetics in chronically hypoxic animals. J. Natl. Cancer Inst. (1970) 45:123-133.
7. FOLKMAN J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285:1182-1186.
8. LI CY, SHAN S, HUANG Q et al.: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J. Natl. Cancer Inst. (2000) 92:143-147.
9. LIOTTA LA, KLEINERMAN J, SAIDEL GM: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. (1974) 34:997-1004.
10. ASAHARA T, MASUDA H, TAKAHASHI T et al.: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. (1999) 85:221-228.
11. ST CROIX B, RAGO C, VELCULESCU V et al.: Genes expressed in human tumor endothelium. Science (2000) 289:1197-1202.
12. WEIDNER N, SEMPLE JP, WELCH WR, FOLKMAN J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. (1991) 324:1-8.
13. WEIDNER N, FOLKMAN J, POZZA F et al.: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. (1992) 84:1875-1887.
14. GASPARINI G, HARRIS AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. Clin. Oncol. (1995) 13:765-782.
15. OBERMAIR A, CZERWENKA K, KURZ C, KAIDER A, SEVELDA P: [Tumoral vascular density in breast tumors and their effect on recurrence-free survival]. Chirurgie (1994) 65:611-615. German.
16. TOI M, KASHITANI J, TOMINAGA T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int. J. Cancer. (1993) 55:371-374.
17. VISSCHER DW, SMILANETZ S, DROZDOWICZ S, WYKES SM: Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal. Quant. Cytol. Histol. (1993) 15:88-92.
18. HORAK ER, LEEK R, KLENK N et al.: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet (1992) 340:1120-1124.
19. BOSARI S, LEE AK, DELELLIS RA, WILEY BD, HEATLEY GJ, SILVERMAN ML: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum. Pathol. (1992) 23:755-761.
20. HALL NR, FISH DE, HUNT N, GOLDIN RD, GUILLOU PJ, MONSON JR: Is the relationship between angiogenesis and metastasis in breast cancer real? Surg. Oncol. (1992) 1:223-229.
21. AXELSSON K, LJUNG BM, MOORE DH II et al.: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst. (1995) 87:997-1008.
22. WEIDNER N, CARROLL PR, FLAX J, BLUMENFELD W, FOLKMAN J: Tumor angiogenesis correlates with metastases in invasive prostate carcinoma. Am. J. Pathol. (1993) 143:401-409.
23. FREGENE TA, KHANUJA PS, NOTO AC et al.: Tumor-associated angiogenesis in prostate cancer. Anticancer Res. (1993) 13:2377-2381.
24. GRAHAM CH, RIVERS J, KERBEL RS, STANKIEWICZ KS, WHITE WL: Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am. J. Pathol. (1994) 145:510-514.
25. HOLLINGSWORTH HC, KOHN EC, STEINBERG SM, ROTHENBERG ML, MERINO MJ: Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. (1995) 147:33-41.
26. MAEDA K, CHUNG YS, TAKATSUKA S et al.: Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br. J. Cancer (1995) 72:319-323.
27. TAKAHASHI Y, KITADAI Y, BUCANA CD, CLEARY KR, ELLIS LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. (1995) 55:3964-3968.
28. MATTERN J, KOOMAGI R, VOLM M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br. J. Cancer (1996) 73:931-934.
29. VOLM M, KOOMAGI R, MATTERN J: Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer (1997) 74:64-68.
30. TAKANAMI I, TANAKA F, HASHIZUME T, KODAIRA S: Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. (1997) 17:2811-2814.
31. HLATKY L, HAHNFELDT P, FOLKMAN J: Clinical application of antiangiogenic therapy; microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. (2002) 94:883-893.
32. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86:353-364.
33. PLOUET J, SCHILLING J, GOSPODAROWICZ D: Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J. (1989) 8:3801-3806.
34. SHWEIKI D, ITIN A, SOFFER D, KESHET E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 359:843-845.
35. GROTENDORST GR, SOMA Y, TAKEHARA K, CHARETTE M: EGF and TGF-α are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J. Cell. Physiol. (1989) 139:617-623.
36. PLOUET J, GOSPODAROWICZ D: Transforming growth factor β-1 positively modulates the bioactivity of fibroblast growth factor on corneal endothelial cells. J. Cell. Physiol. (1989) 141:392-399.
37. SZEKANECZ Z, SHAH MR, HARLOW LA, PEARCE WH, KOCH AE: Interleukin-8 and tumor necrosis factor-α are involved in human aortic endothelial cell migration. The possible role of these cytokines in human aortic aneurysmal blood vessel growth. Pathobiology (1994) 62:134-139.
38. BICKNELL R, VALLEE BL: Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2. Proc. Natl. Acad. Sci. USA (1989) 86:1573-1577
39. BATTEGAY EJ, RUPP J, IRUELA-ARISPE L, SAGE EH, PECH M: PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF β-receptors. J. Cell Biol. (1994) 125:917-928.
40. HUANG YQ, LI JJ, HU L, LEE M, KARPATKIN S: Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb. Haemost. (2001) 86:1094-1098.
41. DAVIS S, ALDRICH TH, JONES PF et al.: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 87:1161-1169.
42. FERRARA N, DAVIS-SMYTH T: The biology of vascular endothelial growth factor. Endocr. Rev. (1997) 18:4-25.
43. MINCHENKO A, BAUER T, SALCEDA S, CARO J: Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab. Invest. (1994) 71:374-379.
44. LIU Y, COX SR, MORITA T, KOUREMBANAS S: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ. Res. (1995) 77:638-643.
45. FINKENZELLER G, TECHNAU A, MARME D: Hypoxia-induced transcription of the vascular endothelial growth factor gene is independent of functional AP-1 transcription factor. Biochem. Biophys. Res. Commun. (1995) 208:432-439.
46. MUKHOPADHYAY D, TSIOKAS L, ZHOU XM, FOSTER D, BRUGGE JS, SUKHATME VP: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature (1995) 375:577-581.
47. OKAZAKI IJ, MOSS J: Mono-ADP-ribosylation: a reversible posttranslational modification of proteins. Adv. Pharmacol. (1996) 35:247-280.
48. GOLDMAN CK, KIM J, WONG WL, KING V, BROCK T, GILLESPIE GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell. (1993) 4:121-133.
49. WARREN RS, YUAN H, MATLI MR, FERRARA N, DONNER DB: Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem. (1996) 271:29483-29488.
50. COHEN T, NAHARI D, CEREM LW, NEUFELD G, LEVI BZ: Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. (1996) 271:736-741.
51. LI J, PERRELLA MA, TSAI JC et al.: Induction of vascular endothelial growth factor gene expression by interleukin-1 β in rat aortic smooth muscle cells. J. Biol. Chem. (1995) 270:308-312.
52. RAK J, MITSUHASHI Y, BAYKO L et al.: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. (1995) 55:4575-4580.
53. MUKHOPADHYAY D, TSIOKAS L, SUKHATME VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. (1995) 55:6161-6165.
54. GOOD DJ, POLVERINI PJ, RASTINEJAD F et al.: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA (1990) 87:6624-6628.
55. FERRARA N, CLAPP C, WEINER R: The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology (1991) 129:896-900.
56. MAIONE TE, GRAY GS, PETRO J et al.: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science (1990) 247:77-79.
57. O'REILLY MS, HOLMGREN L, SHING Y et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 79:315-328.
58. O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88:277-285.
59. O'REILLY MS, PIRIE-SHEPHERD S, LANE WS, FOLKMAN J: Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science (1999) 285:1926-1928.
60. UEBA T, NOSAKA T, TAKAHASHI JA et al.: Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc. Natl. Acad. Sci. USA (1994) 91:9009-9013.
61. DAMERON KM, VOLPERT OV, TAINSKY MA, BOUCK N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 265:1582-1584.
62. RAK J, YU JL, KERBEL RS, COOMBER BL: What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res. (2002) 62:1931-1934.
63. KERBEL RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays (1991) 13:31-36.
64. FOLKMAN J, HAHNFELDT P, HLATKY L: Cancer: looking outside the genome. Nat. Rev. Mol. Cell. Biol. (2000) 1:76-79.
65. STOLER DL, CHEN N, BASIK M et al.: The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Natl. Acad. Sci. USA (1999) 96:15121-15126.
66. BOEHM T, FOLKMAN J, BROWDER T, O'REILLY MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390:404-407.
67. GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293:876-880.
68. HIDALGO M, ECKHARDT SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. (2001) 93:178-193.
69. PEPPER MS: Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. (2001) 21:1104-1117.
70. COUSSENS LM, FINGLETON B, MATRISIAN LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 295:2387-2392.
71. MUSTONEN T, ALITALO K: Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol. (1995) 129:895-898.
72. GLUZMAN-POLTORAK Z, COHEN T, HERZOG Y, NEUFELD G: Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J. Biol. Chem. (2000) 275:18040-18045.
73. REYES M, DUDEK A, JAHAGIRDAR B, KOODIE L, MARKER PH, VERFAILLIE CM: Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. (2002) 109:337-346.
74. INOUE M, HAGER JH, FERRARA N, GERBER HP, HANAHAN D: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell (2002) 1:193-202.
75. TOI M, MATSUMOTO T, BANDO H: Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. (2001) 2:667-673.
76. YONEKURA H, SAKURAI S, LIU X et al.: Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J. Biol. Chem. (1999) 274:35172-35178.
77. HIRATSUKA S, MARU Y, OKADA A, SEIKI M, NODA T, SHIBUYA M: Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. (2001) 61:1207-1213.
78. PARK JE, CHEN HH, WINER J, HOUCK KA, FERRARA N: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. (1994) 269:25646-25654.
79. LUTTUN A, TJWA M, MOONS L et al.: Revascularization of ischemic tissues by P1GF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. (2002) 8:831-840.
80. OURA H, BERTONCINI J, VELASCO P, BROWN LF, CARMELIET P, DETMAR M: A critical role of placental growth factor in the induction of inflammation and edema formation. Blood (2003) 101:560-567.
81. LUTTUN A, BRUSSELMANS K, FUKAO H et al.: Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem. Biophys. Res. Commun. (2002) 295:428-434.
82. KOBLIZEK TI, WEISS C, YANCOPOULOS GD, DEUTSCH U, RISAU W: Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol. (1998) 8:529-532.
83. PAPAPETROPOULOS A, FULTON D, MAHBOUBI K et al.: Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem. (2000) 275:9102-9105.
84. SHIM WS, TEH M, BAPNA A et al.: Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp. Cell Res. (2002) 279:299-309.
85. MAISONPIERRE PC, SURI C, JONES PF et al.: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 277:55-60.
86. HOLASH J, MAISONPIERRE PC, COMPTON D et al.: Vessel co-option, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 284:1994-1998.
87. TANAKA F, ISHIKAWA S, YANAGIHARA K et al.: Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. (2002) 62:7124-7129.
88. MAIONE TE, GRAY GS, HUNT AJ, SHARPE RJ: Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res. (1991) 51:2077-2083.
89. GENGRINOVITCH S, GREENBERG SM, COHEN T et al.: Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J. Biol. Chem. (1995) 270:15059-15065.
90. PEROLLET C, HAN ZC, SAVONA C, CAEN JP, BIKFALVI A: Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood (1998) 91:3289-3299.
91. LOZANO RM, REDONDO-HORCAJO M, JIMENEZ MA et al.: Solution structure and interaction with basic and acidic fibroblast growth factor of a 3 kDa human platelet factor-4 fragment with antiangiogenic activity. J. Biol. Chem. (2001) 276:35723-35734.
92. JOUAN V, CANRON X, ALEMANY M et al.: Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood (1999) 94:984-993.
93. GENTILINI G, KIRSCHBAUM NE, AUGUSTINE JA, ASTER RH, VISENTIN GP: Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). Blood (1999) 93:25-33.
94. DAWSON DW, PEARCE SF, ZHONG R, SILVERSTEIN RL, FRAZIER WA, BOUCK NP: CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. (1997) 138:707-717.
95. JIMENEZ B, VOLPERT OV, CRAWFORD SE, FEBBRAIO M, SILVERSTEIN RL, BOUCK N: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. (2000) 6:41-48.
96. JIMENEZ B, VOLPERT OV, REIHER F et al.: c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene (2001) 20:3443-3448.
97. IRUELA-ARISPE ML, LOMBARDO M, KRUTZSCH HC, LAWLER J, ROBERTS DD: Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the Type 1 repeats. Circulation (1999) 100:1423-1431.
98. BEIN K, SIMONS M: Thrombospondin Type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J. Biol. Chem. (2000) 275:32167-32173.
99. DAVIES CDE L, MELDER RJ, MUNN LL, MOUTA-CARREIRA C, JAIN RK, BOUCHER Y: Decorin inhibits endothelial migration and tube-like structure formation: role of thrombospondin-1. Microvasc. Res. (2001) 62:26-42.
100. FILLEUR S, VOLPERT OV, DEGEORGES A et al.: In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev. (2001) 15:1373-1382.
101. STREIT M, RICCARDI L, VELASCO P et al.: Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc. Natl. Acad. Sci. USA (1999) 96:14888-14893.
102. KUNZ M, KOCZAN D, IBRAHIM SM, GILLITZER R, GROSS G, THIESEN HJ: Differential expression of thrombospondin 2 in primary and metastatic malignant melanoma. Acta Derm. Venereol. (2002) 82:163-169.
103. LYDEN D, YOUNG AZ, ZAGZAG D et al.: Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature (1999) 401:670-677.
104. BENEZRA R, RAFII S, LYDEN D: The Id proteins and angiogenesis. Oncogene (2001) 20:8334-8341.
105. 3 for angiogenesis, Science (1994) 264:569-571.
106. 2(+)-dependent cell - cell adhesion molecule in endothelial cells. J. Cell Biol. (1990) 110:1745-1756.
107. LAMPUGNANI MG, RESNATI M, DEJANA E, MARCHISIO PC: The role of integrins in the maintenance of endothelial monolayer integrity. J. Cell Biol. (1991) 112:479-490.
108. RUPP PA, LITTLE CD: Integrins in vascular development. Circ. Res. (2001) 89:566-572.
109. 5 integrins. Nat. Med. (2002) 8:27-34.
110. HYNES RO: A reevaluation of integrins as regulators of angiogenesis. Nat. Med. (2002) 8:918-921.
111. CARMELIET P: Integrin indecision. Nat. Med. (2002) 8:14-16.
112. (3 integrin and inhibits angiogenesis. J. Biol. Chem. (2001) 276:31959-31968.
113. MAESHIMA Y, SUDHAKAR A, LIVELY JC et al.: Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (2002) 295:140-143.
114. PATTERSON BC, SANG QA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. (1997) 272:28823-28825.
115. DONG Z, KUMAR R, YANG X, FIDLER IJ: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell (1997) 88:801-810.
116. GATELY S, TWARDOWSKI P, STACK MS et al.: The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA (1997) 94:10868-10872.
117. ABAD MC, ARNI RK, GRELLA DK, CASTELLINO FJ, TULINSKY A, GEIGER JH: The X-ray crystallographic structure of the angiogenesis inhibitor angiostatin. J. Mol. Biol. (2002) 318:1009-1017.
118. GUPTA N, NODZENSKI E, KHODAREV NN et al.: Angiostatin effects on endothelial cells mediated by ceramide and RhoA. EMBO Rep. (2001) 2:536-540.
119. YAMAZAKI Y, TSURUGA M, ZHOU D et al.: Cytoskeletal disruption accelerates caspase-3 activation and alters the intracellular membrane reorganization in DNA damage-induced apoptosis. Exp. Cell Res. (2000) 259:64-78.
120. MOSER TL, KENAN DJ, ASHLEY TA et al.: Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc. Natl. Acad. Sci. USA (2001) 98:6656-6661.
121. WAHL ML, GRANT DS: Effects of microenvironmental extracellular pH and extracellular matrix proteins on angiostatin's activity and on intracellular pH. Gen. Pharmacol. (2000) 35:277-285.
122. BENELLI R, MORINI M, CARROZZINO F et al.: Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J. (2002) 16:267-269.
123. WEN W, MOSES MA, WIEDERSCHAIN D, ARBISER JL, FOLKMAN J: The generation of endostatin is mediated by elastase. Cancer Res. (1999) 59:6052-6056.
124. HOHENESTER E, SASAKI T, OLSEN BR, TIMPL R: Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J. (1998) 17:1656-1664.
125. YAMAGUCHI N, ANAND-APTE B, LEE M et al.: Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. (1999) 18:4414-4423.
126. JOUANNEAU E, ALBERTI L, NEJJARI M et al.: Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J. Neurooncol. (2001) 51:11-18.
127. RICHARDSON P, HIDESHIMA T, ANDERSON K: Thalidomide: emerging role in cancer medicine. Annu. Rev. Med. (2002) 53:629-657.
128. FUJITA J, MESTRE JR, ZELDIS JB, SUBBARAMAIAH K, DANNENBERG AJ: Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res. (2001) 7:3349-3355.
129. SIEMANN DW, ROJIANI AM: Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54:1512-1517.
130. SIEMANN DW, MERCER E, LEPLER S, ROJIANI AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer (2002) 99:1-6.
131. TOZER GM, PRISE VE, WILSON J et al.: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. (1999) 59:1626-1634.
132. CRISTOFANILLI M, CHARNSANGAVEJ C, HORTOBAGYI GN: Angiogenesis modulation in cancer research: novel clinical approaches. Nat. Rev. Drug Discov. (2002) 1:415-426.
133. HOLMGREN L, O'REILLY MS, FOLKMAN J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. (1995) 1:149-153.
134. MUNDHENKE C, THOMAS JP, WILDING G et al.: Tissue examination to monitor antiangiogenic therapy: a Phase I clinical trial with endostatin. Clin. Cancer Res. (2001) 7:3366-3374.
135. HERBST RS, HESS KR, TRAN HT et al.: Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. (2002) 20:3792-3803.
136. EDER JP Jr, SUPKO JG, CLARK JW et al.: Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol. (2002) 20:3772-3784.
137. BRAMHALL SR, ROSEMURGY A, BROWN PD, BOWRY C, BUCKELS JA: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. (2001) 19:3447-3455.
138. DEVORE R, FAHRENBACHER L, HERBST R: A randomized Phase II trial comparing recombinant humanized monoclonal antibody to vascular endothelial growth factor plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc. Am. Soc. Oncol. (2000). Abstract 1896, 485a.
139. SLEDGE G, MILLER K, NOVOTNY W, GAUDREAULT J, ASH M, COBLEIGH M: A Phase II trial of single agent recombinant humanized monoclonal antibody to vascular endothelial growth factor in patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19. Abstract 5c, 3a.
140. REESE D, FROHLICH M, BOOK R: A Phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18. Abstract 1355, 351a.
141. BERGSLAND E, HURWITZ H, FAHRENBACHER L: A randomized Phase II trial comparing rhuMabVEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19. Abstract 939, 242a.
142. YANG J, HAWORTH L, STEINBERG SM, ROSENBERG SA, NOVOTNY W: A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21. Abstract 15, 5a.
143. MORIMOTO K, WEST HA, YUEN WR, MATHEWS C, BELLO G: Biomarker analysis of patients samples from a Phase I clinical trial using the angiogenesis inhibitor, SU-6668, for treatment of advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21. Abstract 336, 85a.
144. SANDBERG JA: Pharmacology and toxicology of an antiangiogenic ribozyme. IBC 5th Annual Conference: Angiogenesis: novel therapeutic development, Boston. March 1999.
145. BELMAN N, BONNEM EM, HARVEY AH, LIPTON A: Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest. New Drugs (1996) 14:387-389.
146. DE VOS FYFL, HOEKSTRA R, GIETEMA JA et al.: A Phase I dose escalating study of the angiogenesis inhibitor thrombospondin-mimetis (ABT-510) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:82a.
147. 3. Clin. Cancer Res. (2000) 6:3056-3061.
148. TAGA T, SUZUKI A, GONZALEZ-GOMEZ I et al.: α v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int. J. Cancer (2002) 98:690-697.
149. FIGG WD, KRUGER EA, PRICE DK, KIM S, DAHUT WD: Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest. New Drugs (2002) 20:183-194.
150. BAIDAS SM, WINER EP, FLEMING GF et al.: Phase II evaluation of thalidomide in patients with metastatic breast cancer. J. Clin. Oncol. (2000) 18:2710-2717.
151. BHARGAVA P, MARSHALL JL, DAHUT W et al.: A Phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin. Cancer Res. (2001) 7:3912-3919.
152. BLANKE CD: Celecoxib with chemotherapy in colorectal cancer. Oncology (Huntingt.) (2002) 16:17-21.
153. GLASPY JA: Therapeutic options in the management of renal cell carcinoma. Semin. Oncol. (2002) 29:41-46.
154. PRIBLUDA VS, GUBISH ER Jr, LAVALLEE TM, TRESTON A, SWARTZ GM, GREEN SJ: 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. (2000) 19:173-179.
155. TAKEUCHI E, YANAGAWA H, SUZUKI Y et al.: IL-12-induced production of IL-10 and interferon-γ by mononuclear cells in lung cancer-associated malignant pleural effusions. Lung Cancer (2002) 35:171-177.
156. PIKE SE, YAO L, JONES KD et al.: Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J. Exp. Med. (1998) 188:2349-2356.
157. RAMCHANDRAN R, DHANABAL M, VOLK R et al.: Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem. Biophys. Res. Commun. (1999) 255:735-739.
158. VAJKOCZY P, MENGER MD, GOLDBRUNNER R et al.: Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. Int. J. Cancer (2000) 87:261-268.
159. SHIMO T, NAKANISHI T, KIMURA Y et al.: Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells. J. Biochem. (Tokyo) (1998) 124:130-140.
160. KOCH AE, POLVERINI PJ, KUNKEL SL et al.: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science (1992) 258:1798-1801.
161. GASPARINI G: Metronomic scheduling: the future of chemotherapy? Lancet Oncol. (2001) 2:733-740.
162. BROWDER T, BUTTERFIELD CE, KRALING BM et al.: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. (2000) 60:1878-1886.
163. MARKMAN M, HALL J, SPITZ D et al.: Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J. Clin. Oncol. (2002) 20:2365-2369.
164. STERBA J, PAVELKA Z, SLAMPA P: Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma (2002) 49:117-120.
165. LITTLE RF, WYVILL KM, PLUDA JM et al.: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. (2000) 18:2593-2602.
166. YOKOYAMA Y, DHANABAL M, GRIFFIOEN AW, SUKHATME VP, RAMAKRISHNAN S: Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. (2000) 60:2190-2196.
167. MINISCHETTI M, VACCA A, RIBATTI D et al.: TNP-470 and recombinant human interferon-α2a inhibit angiogenesis synergistically. Br. J. Haematol. (2000) 109:829-837.
168. DABROWSKA A, GIERMASZ A, MARCZAK M, GOLAB J, JAKOBISIAK M: Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice. Anticancer Res. (2000) 20:391-394.
169. SALCEDO R, PONCE ML, YOUNG HA et al.: Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood (2000) 96:34-40.
170. KERBEL RS, YU J, TRAN J et al.: Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. (2001) 20:79-86.
171. BERGERS G, JAVAHERIAN K, LO KM, FOLKMAN J, HANAHAN D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 284:808-812.
172. GROVES MD, PUDUVALLI VK, HESS KR et al.: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. (2002) 20:1383-1388.
173. MANIOTIS AJ, FOLBERG R, HESS A et al.: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. (1999) 155:739-752.
174. FOLBERG R, HENDRIX MJ, MANIOTIS AJ: Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. (2000) 156:361-381.
175. HAO X, SUN B, ZHANG S, ZHAO X: Microarray study of vasculogenic mimicry in bi-directional differentiation malignant tumor. Zhonghua Yi Xue Za Zhi (2002) 82:1298-1302.
176. FAUSTO N: Vasculogenic mimicry in tumors. Fact or artifact? Am. J. Pathol. (2000) 156:359.
177. SKOBE M, HAWIGHORST T, JACKSON DG et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. (2001) 7:192-198.
178. CLARIJS R, RUITER DJ, DE WAAL RM: Lymphangiogenesis in malignant tumours: Does it occur? J. Pathol. (2001) 193:143-146.
179. KARPANEN T, EGEBLAD M, KARKKAINEN MJ et al.: Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. (2001) 61:1786-1790.
180. CASSELLA M, SKOBE M: Lymphatic vessel activation in cancer. Ann. NY Acad. Sci. (2002) 979:120-130.
181. YU JL, COOMBER BL, KERBEL RS: A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation (2002) 70:599-609.
182. YU JL, RAK JW, COOMBER BL, HICKLIN DJ, KERBEL RS: Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 295:1526-1528.
183. FERRARA N, LECOUTER J, LIN R: Endocrine gland vascular endothelial growth factor (EG-VEGF) and the hypothesis of tissue-specific regulation of angiogenesis. Endocr. Res. (2002) 28:763-764.
184. LECOUTER J, LIN R, FERRARA N: Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat. Med. (2002) 8:913-917.
185. GORSKI DH, MAUCERI HJ, SALLOUM RM et al.: Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. (1998) 58:5686-5689.
186. MAUCERI HJ, HANNA NN, BECKETT MA et al.: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (1998) 394:287-291.
187. QIAN CN, MIN HQ, LIN HL, HONG MH: Combination of angiogenesis inhibitor TNP-470 with cytotoxic drugs in experimental therapy of nasopharyngeal carcinoma. Ann. Otol. Rhinol. Laryngol. (2000) 109:641-645.
188. TEICHER BA, HOLDEN SA, ARA G et al.: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer. (1994) 57:920-925.
189. JAIN RK, CARMELIET PF: Vessels of death or life. Sci. Am. (2001) 285:38-45.
190. BISSETT D, VON PAWEL J, MERCIER R et al.: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2002) 21. Abstract 1183, 296a.